Strong Momentum Drives Venus Remedies to New Heights
On 24 Nov 2025, Venus Remedies recorded an intraday peak at Rs.728, representing its highest price level in the past year and an all-time high for the company. The stock outperformed its sector by 1.47% during the trading session, with a day’s gain of 1.82%. This marks the fourth consecutive day of gains, during which the stock has delivered a cumulative return of 28.3%.
The stock’s performance is further highlighted by its position above key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. Such technical indicators often signal sustained strength and investor confidence in the stock’s price action.
Market Context and Sector Performance
The broader market environment has also been supportive. The Sensex opened 88.12 points higher and was trading at 85,455.79, just 0.4% shy of its own 52-week high of 85,801.70. The index has been on a three-week consecutive rise, gaining 2.69% over this period, with mega-cap stocks leading the advance. The Sensex’s position above its 50-day moving average, which itself is above the 200-day moving average, reflects a bullish trend that has coincided with Venus Remedies’ upward movement.
From struggle to strength! This Small Cap from Textile - Machinery is showing early turnaround signals that look promising. Position yourself now for explosive growth potential ahead!
- - Early turnaround signals
- - Explosive growth potential
- - Textile - Machinery recovery play
Position for Explosive Growth →
Long-Term Performance and Valuation Metrics
Venus Remedies has demonstrated remarkable performance over the past year, with a return of 142.67%, significantly outpacing the Sensex’s 8.01% return during the same period. The stock’s 52-week low was Rs.272.20, highlighting the extent of its price appreciation over the last twelve months.
Financially, the company’s net profit has shown a substantial rise, with a quarterly PAT of Rs.20.13 crores reflecting a growth of 473.5%. The company has reported positive results for four consecutive quarters, indicating consistent operational performance. Additionally, the return on capital employed (ROCE) for the half-year period stands at 13.99%, while the inventory turnover ratio is at 6.58 times, both figures representing strong operational efficiency.
Venus Remedies’ return on equity (ROE) is recorded at 10.5%, and the stock trades at a price-to-book value of 1.6, suggesting an attractive valuation relative to its peers. The company’s debt-to-equity ratio remains low, averaging zero, which points to a conservative capital structure.
Sector and Peer Comparison
Within the Pharmaceuticals & Biotechnology sector, Venus Remedies stands out for its market-beating performance both in the near term and over longer horizons. The stock has outperformed the BSE500 index over the last three years, one year, and three months, underscoring its resilience and growth trajectory within the sector.
Get the full story on Venus Remedies ! Our detailed research dives into fundamentals, sector comparison, technical analysis, and valuations for this Pharmaceuticals & Biotechnology micro-cap. Make informed decisions!
- - Full research story
- - Sector comparison done
- - Informed decision support
Market Participation and Shareholding Insights
Despite the company’s size and performance, domestic mutual funds currently hold no stake in Venus Remedies. This absence of mutual fund participation may reflect a cautious stance or differing assessment of the stock’s valuation or business prospects. Such a scenario is noteworthy given that domestic mutual funds typically conduct in-depth research and often hold positions in companies with strong fundamentals.
The stock’s recent price action and fundamental metrics, however, indicate a phase of robust momentum and operational strength, as evidenced by its new 52-week high and consistent quarterly results.
Summary of Key Metrics
To summarise, Venus Remedies’ key financial and market indicators include:
- New 52-week and all-time high price of Rs.728
- Four consecutive days of gains with a 28.3% return in this period
- Net profit growth of 473.5% in the latest quarter
- ROCE at 13.99% and inventory turnover ratio at 6.58 times for the half-year
- Return on equity of 10.5% and price-to-book value of 1.6
- Debt-to-equity ratio averaging zero
- Outperformance of Sensex and BSE500 indices over multiple timeframes
These figures collectively illustrate the company’s strong operational footing and market performance, culminating in the recent milestone of a new 52-week high.
Limited Time Only! Subscribe for Rs. 12,999 and get 1 Year of MojoOne + an Additional Year Completely FREE. Don't miss out on this exclusive offer. Claim Your Free Year →
